Sort
48,018 grants matching “immunotherapy”
Development of a theragnostic radiopharmaceutical for pancreatic cancer
$638,027Katherine W Ferrara · Stanford University · R01 · FY2025 · CA
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$638,007Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2022 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$637,991James R. Heath · California Institute Of Technology · U54 · FY2015 · CA
Nano immunoconjugates to treat primary and metastatic HER2 positive breast cancer
$637,908Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2020 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$637,881Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2023 · CA
Targeting Neoantigens in Triple Negative Breast Cancer
$637,864William E Gillanders · Washington University · R01 · FY2021 · CA
Targeting Neoantigens in Triple Negative Breast Cancer
$637,836William E Gillanders · Washington University · R01 · FY2020 · CA
Development of a theragnostic radiopharmaceutical for pancreatic cancer
$637,798Katherine W Ferrara · Stanford University · R01 · FY2024 · CA
EpCAM (CD326) Function in Epithelial Cell Biology and Immunophysiology
$637,771Mark Udey · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
T cell Immunity in a Rare Juvenile Form of Motor Neuron Disease
$637,742Ivan Marazzi · University Of California-Irvine · R01 · FY2025 · NS
Preclinical and Clinical Models of Drug Induced Kidney Injury
$637,693Melanie S Joy · University Of Colorado Denver · R01 · FY2023 · CA
Biogenic Gas Nanostructures as Molecular Imaging Reporters for Ultrasound
$637,651Mikhail Shapiro · California Institute Of Technology · R01 · FY2025 · EB
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis
$637,629Monica Shokeen · Washington University · R01 · FY2020 · CA
Synthetic rescue of antigen-driven T cells and alloimmunity
$637,613Jonathan A Soboloff · Temple Univ Of The Commonwealth · R01 · FY2022 · AI
Synthetic rescue of antigen-driven T cells and alloimmunity
$637,613Jonathan A Soboloff · Temple Univ Of The Commonwealth · R01 · FY2021 · AI
Synthetic rescue of antigen-driven T cells and alloimmunity
$637,613Jonathan A Soboloff · Temple Univ Of The Commonwealth · R01 · FY2023 · AI
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
$637,515Paul Nghiem · University Of Washington · R01 · FY2015 · CA
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
$637,515Paul Nghiem · University Of Washington · R01 · FY2016 · CA
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level
$637,486Warren Phipps · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center
$637,440Jason Derek Merker · Univ Of North Carolina Chapel Hill · UG1 · FY2024 · CA
Role of AMPK in melanoma brain metastasis
$637,432Bin Zheng · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells
$637,418Chrystal Mary Paulos · Emory University · R01 · FY2023 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
$637,395Amir Horowitz · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Immunology of aging and immunotherapy of aging-associated diseases
$637,389Arya Biragyn · National Institute On Aging · ZIA · FY2019 · AG
MRI-Guided Cryoablation and Imaging-Guided Intratumoral Delivery of STING Agonist Immunotherapy to Target Localized and Metastatic Canine Osteosarcoma
$637,376Dara L Kraitchman · Johns Hopkins University · R01 · FY2020 · CA